← All trials
NCT03010202
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2016
- Primary completion
- Dec 1, 2023
- Completion date
- Dec 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Ostfold UniversityLead sponsor
- Oslo Metropolitan UniversityCollaborator
- University Hospital of North NorwayCollaborator
- Hopital La RabtaCollaborator
- Tunisian Military HospitalCollaborator
- University of BergenCollaborator
- Osaka UniversityCollaborator
- University of Southern DenmarkCollaborator
- University of StavangerCollaborator
- Norwegian University of Science and TechnologyCollaborator
- Imperial College LondonCollaborator
- CHU Henri MondorCollaborator
- Ostfold UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.